Quest Diagnostics

Bank of America Merrill Lynch Global Healthcare Conference

September 15, 2009

This presentation may contain forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Factors that May Affect Future Results" in Part I, Item 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the company's 2008 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2009 Quarterly Report on Form 10-Q and other items throughout the Form 10-K and the company's 2009 Quarterly Report on Form 10-Q and Current Reports on Form 8-K.

Who is Quest Diagnostics?

Leader in Providing Healthcare Insights and Solutions

Comprehensive Diagnostic Testing

- Routine ——» Esoteric
  - Diagnose
  - Monitor
  - Predict
  - Prevent

Advanced Information Technology Solutions

- Improve Care and Efficiency

Facilitate Introduction of New Therapeutics

- Clinical Trials Testing

Innovative Diagnostic Products

- Enable Care Closer to the Patient

Risk Assessment Solutions to Life Insurance Industry

Touching Patients 150 Million Times Each Year

The Leader in Diagnostic Testing

U.S. Diagnostic Testing Market: > $50 B



Source: Washington G-2 Reports and company information

History of Strong Growth



▲ 20%

Revenue 1999-2008
10-year CAGR 20%



▲ 27%

EPS* 1999-2008
10-year CAGR 27%

$ in billions except EPS
*EPS is from continuing operations

Favorable Industry Trends

Essential Healthcare Service

Growing and Aging Population



Scientific & Medical Innovations

Personal Interest in Health

Convergence of Information

Influences >70% of Healthcare Decisions

Moving to Higher Growth, Higher Margin Testing Segments

2000 Revenue



Total Revenue: $3.4 Billion

2008 Revenue



Total Revenue: $7.2 Billion

Expanding Market Leadership

	2000	2009
Clinical Testing	✓	✓
Gene-based & Esoteric Testing	✓	✓
Employer Services	✓	✓
Anatomic Pathology Testing	P	✓
Risk Assessment Services	-	✓
Healthcare Information Technology	-	✓
Point of Care (Near Patient) Testing	-	✓
Clinical Trials Testing	P	P
International Market	-	P

✓ Overall Market Leader/Niche Leadership

P Market Participant

Our Longer Term Goals

Undisputed World Leader in Diagnostic Testing, Information and Services

Profitably Grow > Industry Rate

Expand Operating Income to 20% of Revenues

Expand International Operations to ~10% of Revenues

Strategy to Drive Profitable Growth

Leverage Capabilities To Create Differentiation

Deliver Superior
Patient Experience

99.9997%

Continuously Drive
Six Sigma Quality

Lead in
Medical Innovation

Leverage Unparalleled
Assets & Capabilities

Expand
Diagnostic Scope

Expand
Geographic Reach

Leading Medical Innovator

Multiple Channels to Access New Technology

- Internal Development – Nichols Institute
- Joint Development Relationships
- Licensing/Distribution Relationships

Focused on Addressing Areas of Significant Patient Need

- Cancer, Cardiovascular Conditions, Infectious Disease
- Less invasive; less painful; more convenient for patients

Leading Experts for Medical Consultation

- 900 MDs & PhDs

Culture of Collaborative Innovation

- Academic relationships
- Investment in innovative firms and technologies
- Partnerships with pharmaceutical companies

Continual Stream of Testing Advances and Technology Innovation

Cancer/Pathology

- EGFR Pathway Reflex Testing
- Molecular Oncology in plasma (Leumeta™)
- Ova1 for Ovarian Cancer
- HE-4 for Ovarian Cancer
- Circulating tumor cells (CellSearch)

Cardiovascular Disease/Endocrinology

- *Plasma renin by LC MSMS*
- Ion Mobility (Lipid Profile)
- Vitamin testing by Mass Spectrometry

Infectious Disease

- H1N1 Diagnostic (Swine flu)
- HIV tropism (CCR5 response to therapy)
- Chikungunya
- Hepascore

Genetics

- Maternal serum screen (Penta screen)
- CGH post-natal testing (Clarisure)
- Warfarin, Plavix ® (CYP450 2C9/2C19)

Transplantation/Coagulation

- HLA FDA-registered lab
- Transplant infections by sequencing
- Panels for menorrhagia and miscarriage
- Aspirin resistance

Technology innovation

- Digital pathology (Inscape)
- Scorpian technology for PCR
- Mass spectrometry proteomics

Italics – under development

H1N1 Virus: From Outbreak to Emergency Use Authorization in 12 Weeks

4/26

4/27

- Genetic sequence of H1N1 virus published online
- Analyze sequences
- Design primers and probes
- Validate test

5/11

6/6

- Complete studies showing 100% agreement with CDC PCR assay
- Apply for Emergency Use Authorization

7/24

The New York Times

World

U.S. Declares Public Health Emergency Over Swine Flu

By DONALD G. McNEIL Jr.
Published: April 26, 2009

Responding to what some health officials feared could be the leading edge of a global pandemic emerging from Mexico, American health officials declared a public health emergency on Sunday as 20 cases of swine flu were confirmed in this country, including eight in New York City.

Other nations imposed travel bans or made plans to quarantine air travelers as confirmed cases also appeared in Mexico and Canada and suspect cases emerged elsewhere.

Bloomberg

Quest Diagnostics Reports First Commercial H1N1 Swine Flu Test

By Jeran Wittenstein
May 11, 2009

May 11 (Bloomberg) -- Quest Diagnostics Inc. said the company has released the first commercial test to help identify the H1N1 swine flu virus.

REUTERS

US FDA OKs use of Quest Diagnostics H1N1 flu test

WASHINGTON, July 24 (Reuters) - U.S. regulators said Friday they authorized emergency use of a Quest Diagnostics Inc (DGX.N) test for the H1N1 swine flu virus.

The test is the third one authorized by the Food and Drug Administration for diagnosing an infection with the pandemic H1N1 virus, the agency said. It is made by Quest unit Focus Diagnostics. (Reporting by Lisa Richwine, editing by Gerald E. McCormick)

ALSO ON REUTERS

National Health Care Reform

Objectives	Impact to Quest Diagnostics
• Expanded Coverage for Uninsured	+
• Emphasis on Prevention, Wellness and Early Detection	+
• Reduce Costs	–
• Expanded HCIT Utilization	+
• Expected Net Impact	+

YTD June 30, 2009 Results

Strong Growth in Earnings and Cash Flow

Revenues	$3.7 B	↑ 2.4%
Operating Income %	18.3%	↑ 210 bp
EPS	$1.89	↑ 22%
Cash from Operations *	$264 M	↓ 29%

*Includes $308 million payment for the previously disclosed NID settlement

2009 Guidance

Continued Revenue & Earnings Growth

Revenues	↑ ~3%
Operating Income %	~ 18%
EPS	$3.70 - $3.80, ↑ 15 - 18%
Cash from Operations *	~$1 billion
CapEx	~$200 million

Improving Operational Efficiencies

*Excludes $308 million payment for the previously disclosed NID settlement

Building on Strength

Leader in a vital and growing industry

Uniquely positioned with unparalleled assets & capabilities

History of disciplined growth and successful acquisitions

Strong cash generator, with a strong balance sheet

Proven management team

Focused on Execution

Quest Diagnostics